Overview
* Cogent Biosciences ( COGT ) reports Q3 net loss of $80.9 mln, up from $70.6 mln in 2024
* Cash position of $390.9 mln expected to fund operations through 2027
* Upcoming PEAK and APEX trial results expected in Nov and Dec 2025
Outlook
* Cogent plans to announce PEAK trial results in November 2025
* Company expects APEX trial results in December 2025
* Cogent aims to submit NDA for bezuclastinib by year-end 2025
Result Drivers
* R&D EXPENSES - Increased R&D expenses due to ongoing clinical trials and preclinical programs
* CASH POSITION - Strong cash position expected to fund operations through 2027
* CLINICAL PROGRESS - Significant progress with upcoming trial results and regulatory submissions
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$80.93
Income mln
Q3 -$83.35
Income mln
from
Operatio
ns
Q3 $83.35
Operatin mln
g
Expenses
Analyst Coverage
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
* The average consensus recommendation for the biotechnology & medical research peer group is "buy"
* Wall Street's median 12-month price target for Cogent Biosciences Inc ( COGT ) is $20.50, about 20.5% above its October 31 closing price of $16.30
Press Release:
For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)